Hidden in Section 2700 of the $1.9 Trillion COVID-19 Relief Bill Is the Reason the Next Great Investment Opportunity Isn’t Renewable Energy, 5G, or Cryptocurrencies…
Here’s How You Could Profit Off the $242 Billion…
Mental Health Revolution
As I write this, more than 50% of Americans have now received their first dose of a COVID-19 vaccine.
And as the rate of infection begins to slow down in many hard-hit areas, there are signs of recovery…
Businesses, public areas, and restaurants are all starting to reopen.
Unfortunately, however, for millions of Americans, the damage has already been done.
Since the pandemic started:
200,000 businesses have closed their doors.[1]
At its worst point, the pandemic caused 22 million Americans to lose their jobs.[2]
Millions even lost their homes entirely.
“…36% of adults reported symptoms of anxiety or depression in June 2020, compared to just 11% in June 2019.” – Kaiser Family Foundation [4]
“There is consistent evidence linking social isolation and loneliness to worse… mental health outcomes” – ScienceDirect [5]
“40.9% of respondents reported at least one adverse mental or behavioral health condition… related to the pandemic…” – CDC [6]
Unfortunately, the pain doesn’t end there.
Because while new businesses will be started and those who lost their jobs may find employment again…
The toll this disease has taken on our mental health will remain for years to come.
The problem is so big, in Section 2700 of Congress’s $1.9 trillion COVID-19 relief bill, a whopping $4.3 billion[3] was allotted toward mental health for both patients and providers.
But that’s only the canary in the coal mine.
Because while COVID-19 may have caused psychological conditions like anxiety and depression to skyrocket, the truth of the matter is the mental health crisis has been raging for over 30 years…
In fact, last year, an incredible $238 billion was spent on mental health services (therapy, medications, etc…).
And that was over 6% of ALL US health spending for the year.[7]
You see, Americans aren’t just suffering through the pandemic, social media, and job insecurity… We’re becoming massively depressed.
In fact, major depression, which is characterized by feelings of sadness, anxiety, and hopelessness, is one of the most common mental illnesses in the world today…
Affecting 6.7% of (over 16 million) American adults each year.[8]
It can be extremely serious and even lead to other diseases as well as a greater risk of suicide.
Depression can lead to increased use of alcohol as a way to cope.
And alcohol abuse can lead to physical dependence and addiction, which then compounds an individual’s depression even more.[9]
Of course, the stress of COVID-19 has exacerbated the symptoms of this serious condition.
But make no mistake: America’s “mental health crisis” will be here long after COVID-19 is gone.
However, one company has aready-made solution they’re in the process of patenting.[10]
That company is Core One Labs Inc. (CLABD).
Hi, I’m James DiGeorgia.*
You might know me as the editor of World Opportunity Investor…
Or you may have seen one of my appearances on CNBC or Fox Business.
You might have even come across me quoted as an expert in The New York Times, USA Today, Los Angeles Times, Money Magazine, or The Chicago Tribune.
Maybe you’ve even read one of my books: The New Bull Market in Gold, The Rise of Gold in the 21st Century, The Global War for Oil, or The Trader’s Great Gold Rush.
Regardless, my specialty has always been discovering stocks right as they’re about to take off.
I mean, that’s exactly what I’ve been doing for the past 40 years…
And today, I’m revealing what I believe is the world’s next cutting edge industry—and its under-the-radar leader—directly to you.
Investing In Solutions to This Mental Health Crisis Could Be the Next Great Bull Market
There are medical treatments for depression…
But it’s important to remember even today’s best antidepressants only work on two-thirds of the people suffering from depression[11].
In the medical community, this condition is known as “treatment-resistant depression.”
At this very moment, there are over 100 million people suffering from treatment-resistant depression worldwide[12].
Not to mention, treatment-resistant depression cost United States employers over $48 billion each year[13] due to…
Missed work…
Low productivity…
And employee turnover.
And that was BEFORE the pandemic even began.
But now, imagine if a company had discovered a brand new solution for depression and addiction… one that worked even in cases of treatment-resistant depression.
Of course, it goes without saying the potential market for that company would be huge…
And for investors looking for solutions to this crisis, my research has revealed one company leading the way with an innovative solution: Core One Labs (CLABD).
Core One Labs (CLABD) is currently conducting scientific research for the development and production of drug compounds that will be used to treat people with depression, addiction and PTSD. [14]
Now, I’m sure you’d want to know what this medicine is and more importantly the company that’s filing patents on a synthetic version of it.
Once I started digging into the facts surrounding this incredible company, I quickly realized they represent a cutting edge opportunity to capture a massive slice of a fast-growing $242 billion market[15].
So, make no mistake…
Soon, the mental health industry will likely be revolutionized.
In fact, this mental health revolution has arrived, and it’s not a moment too soon.
The statistics behind why we need this ‘miracle’ solution now more than ever are staggering…
Even BEFORE the pandemic, depression in all its forms already cost the United States over $210 billion annually[16]…
While internationally, more than 300 million people suffer from major depressive disorders[17]…
Which is precisely why—with the havoc the pandemic has caused—it’s been forecasted that the global antidepressant market doubled last year alone[18]…
And that’s without a solution for treatment-resistant depression.
But the naturally-derived mental health solution I’m about to reveal to you today has been shown to assist in cases of treatment-resistant depression.[19]
[20]
Of course, there must be a reason why you’ve never heard of this solution before, right?
Well, the reason is simple…
Unfortunately for millions of our fellow Americans, this compound is currently illegal.
But as I’m about to prove, that doesn’t mean it’s dangerous.
In fact, the powers that be are quickly recognizing the mistakes of their past.
And as the many health benefits become more apparent, it is increasingly likely that it may be legalized.
Think about marijuana… that was illegal on both the federal and state levels.
But today, it’s rapidly moving down the path to full federal legalization.
What I’m referring to today is a naturally occurring psychedelic compound known as “psilocybin.”
It’s found in over 200 types of mushrooms and when ingested it causes chemical changes in the brain.
Now, at high doses, these changes can cause hallucinogenic effects.
But at low doses, there are no known negative side effects.
And even though psilocybin is illegal right now… That’s changing as fast as you can say, “Oregon.”
“Oregon Legalizes Psilocybin Mushrooms…” – Forbes[21]
That’s right. As of February 2021, psilocybin is legal in Oregon for medical use in psychiatric settings.
And that means…
Today, There’s a Novel Solution for Successfully Treating Depression
The global psychedelics market is forecast to grow at a massive 16% rate over the coming decade[22]…
And the reason behind this massive growth is clear: Low doses of psilocybin have already been proven to be incredibly effective in treating depression.[23]
An excellent reason to put Core One Labs (CLABD) on your stock watch list.
The key to treatment is using what are referred to as “microdoses” in highly clinical settings.
Now, this isn’t an “out-there” treatment at all.
In fact, there are TED Talks being given about this exact same phenomenon right now.[24]
And media personalities as well-known as Joe Rogan are already endorsing it.[25]
Microdoses are extremely small amounts of the psychedelic compound.
They aren’t enough to produce hallucinations or anything of the sort.
They simply boost the patient’s mood.
And clinical results have shown that microdosing used in conjunction with a psychotherapy program is safe and effective.[26]
In other words, what we’re talking about right now is a highly successful all-natural, non-traditional solution that works where other treatments have failed when used in conjunction with traditional therapy.
And that’s the precise formula Core One Labs (CLABD) is pioneering.
A Well-Formulated Business Model That Virtually Guarantees Massive Profits
Core One Labs (CLABD) currently runs two Canadian clinics with an existing database of over 200,000 patients.[27]
And as U.S. legislation plays catch up, they plan on leveraging their data-driven research to roll out clinics across Canada.[28]
That’s right. Just like with cannabis, the Canadians have beaten America to the punch with this one.
And that means right now is the time for forward-thinking investors to start researching this burgeoning industry…
Now, a typical psilocybin treatment is 6 dosing sessions followed by 3 therapeutic integration sessions.[29]
That means after receiving microdoses of the chemical, the patient meets with a therapist regularly to discuss their experiences.
And that means, with the help of their clinical model, Core One Lab’s (CLABD) clinic patients has secured recurring revenue. [30]
Plus, Core One Labs (CLABD) currently has the exclusive right—issued by Health Canada—to use an operational lab facility to produce psilocybin in Canada.[31]
But Treating Depression Is Only the First Step in the Mental Health Revolution
And alcoholism doesn’t have a sufficient pharmacological solution yet either.[34]
In addition to depression…
Obsessive-compulsive disorder (OCD) affects approximately 7,000,000 Americans.[32]
And it’s completely untreatable with traditional antidepressants.[33]
Then, there’s alcoholism, which costs the U.S. an additional $249 billion each year.
Add it all up… and with no existing treatments, alcoholism and other mental health issues cost the United States alone roughly $450 billion each year.
But psilocybin has exhibited therapeutic benefits in treating OCD.
And it’s been shown to aid those suffering from alcoholism.
You read that right…
Psilocybin can radically decrease the alcohol intake of those addicted for up to 36 weeks after use.[35]
[36]
Simply put, Core One Labs (CLABD) is poised to succeed where many other companies have historically failed…
In offering a profitable solution to some of the most pressing issues our nation faces today.
New Opportunities Like Core One Labs (CLABD) Come Along Once in a Generation
Of course, some investors are betting big on the return of marijuana stocks.
And no one can deny the future is bright for that sector.
In fact, after the 2020 election, 15 states plus Washington, DC, have legalized recreational marijuana…[37]
While a total of 38 states now allow medical use of the controlled substance.[38]
[39] And that’s the same path I expect psilocybin to follow.
Take a big name player like Aurora Cannabis (ACB) for example.
From July 2014 until December 2017—during the height of the marijuana boom—ACB rocketed up an incredible +1,611%…[40]
[41] Or what about Canopy Growth (CGC).
With recent legislative moves following the 2020 election, they’re rapidly returning to their 2018 highs…
And as public opinion about controlled substances such as cannabis continues to shift, that’s the exact same kind of potential I see with psychedelics… especially from an under-the-radar industry leader like Core One Labs (CLABD).
Not One, But Five Patents Pending Give Core One Labs (CLABD) a Significant Advantage
At this very moment, Core One Labs (CLABD) already has several major patents pending.[43]
The first patent pending is for a state-of-the-art distribution system for psilocybin.
[44] This allows for efficient absorption of the chemical, which can be administered in extremely precise microdoses to the patient.
Core One Labs (CLABD) has also several patents pending for psychedelic-based drug formulations to treat Alzheimer’s, stroke, Parkinson’s and depression.[45]
And its team is filing a patent for a unique and highly effective biosynthetic form of psilocybin—meaning this natural compound can be made efficiently and effectively at scale.
And this lab-grown psilocybin gives Core One Labs (CLABD) strict control over the quality and manufacture of their product, which—when it comes to naturally occurring compounds—is a significant advantage.
In fact, it means…
They don’t have to wait for mushrooms to mature.
And they don’t have to worry about ineffectual dosages.
In other words, Core One Labs (CLABD) controls their own product.
On top of that, Core One Labs’ (CLABD) believes it’s biosynthesized , pharma-grade psilocybin can be produced for just $10s- to $100s of dollars per gram…[46]
But it’s then valued at $7,000-$10,000 per gram in clinical trials.[47]
That’s a whopping 98% gross profit margin! *
And that means, not only is this patent-pending product pure and accurate, it’s also extremely profitable.
And should it become a patented product, this compound could then be used not only in Core One Labs’ (CLABD) own clinics…
It could be sold to other pharmaceutical companies for distribution… exponentially increasing the company’s revenue.
And all this means—like many great companies today—Core One Labs (CLABD) is following the “Starbucks” model of growth, by owning their entire supply chain from origin to distribution.
And we all know what Starbucks has been able to do since it went public in 1992…
[48] Investors have seen an unbelievable 11,000% return!*
Not only that, but Core One Labs (CLABD) is already extremely well-funded, with over $20 million of invested capital already.
That means major investors have already seen the potential here.
Why You Should to Look Into This Booming Market… Before It’s on Wall Street’s Radar
Now, as of February 1, 2021, psilocybin or magic mushrooms are legal in the state of Oregon for medicinal purposes in a supervised setting.[49]
But that’s just the beginning.
They’ve been decriminalized in four American cities and the District of Columbia.[50]
And the domino effect could happen fast.
You see, back in 2018, the U.S. Food and Drug Administration began granting companies the right to study psilocybin as a treatment for depression.[51]
And as more and more discoveries are made about the value of using psychedelic compounds to treat a wide range of mental health issues, the entire country moves closer to full legalization.
In fact, the legal psychedelic marketplace is forecasted to be nearly a $6.9 billion business by 2027![52]*
This also shows why it’s a perfect time to check out the huge growth potential for Core One Labs (CLABD).
Of course, we’ve seen this scenario come to pass before with cannabis.
For example, a mere ten years ago, only half of all Americans believed cannabis should be legal.[53]
While today, 90% of all Americans support full legalization of marijuana.[54]
That’s a nearly 100% increase in only a decade!
And it’s proof that opinions and trends regarding once illegal substances are quickly changing.
Of course, the goal here—just like with cannabis before—is to get in early on a profitable psychedelics company with the background, experience, and results needed to become a major player in this burgeoning industry… before Wall Street gets a hold of them.
That’s because as an early investor in one of these companies, your potential for profits is exponential.
While the truth is, once the cat’s out of the bag, the institutional investors will begin raking in all the profits just for themselves.
So, savvy investors should act now before Wall Street catches on to the potential here.*
Strong Leadership Is Setting Up Core One Labs (CLABD) for Massive Success
Core One Labs’ (CLABD) leadership team is no stranger to the worlds of startups, biotech, or even alternative medicine.
Their Executive Chairman, Dr. Robert Hancock, is a world-leading microbiologist who’s researched and taught at the University of British Columbia for nearly 40 years.
This gives him the technical background necessary to implement Core One Labs’ (CLABD) psychedelic solutions.
In fact, he’s published more than 670 papers and reviews and has been awarded nearly 55 patents.[55]
And these accomplishments have led him into business before.
In addition to his work with Core One Labs (CLABD), Dr. Hancock is also the co-founder of Migenix, Inimex Pharmaceuticals, ABT Innovations, Sepset Biosciences, and the Centre for Drug Research and Development.
And as far as leadership goes, not only does Dr. Hancock have a strong educational and research background, CEO Joel Shacker has spent the past seven years working extensively in the fields of finance and cannabis.
As the CEO of cannabis company Thoughtful Brands Inc., he led the company from being a non-revenue generating entity to generating over $30,000,000 per year.[56]
In addition, he’s been on the board of numerous companies that have raised over $50,000,000 in capital.[57]
In fact, his expertise in the medical cannabis market coupled with his business acumen have led him to be considered one of the top young CEOs in public markets today.
That’s because he’s acquired and integrated over 20 different assets across multiple industries.
And these integrations have resulted in a career of over $150,000,000 in total acquisitions[58].
9 Reasons Why Core One Labs (CLABD) is Well-Positioned for the Burgeoning Psychedelic Medicines Boom
Approximately 100 million (or one-third) of all people diagnosed with depression suffer from treatment-resistant depression, and don’t respond to traditional antidepressants. And the FDA has designated psilocybin a “breakthrough therapy” for severe depression.[59]
Psilocybin has shown positive benefits in treating OCD and alcoholism as well.[60]
Core One Labs (CLABD) has not only one but five patents pending for:[61]
A thinstrip delivery mechanism for better absorption and optimal dosing.
Four patents pending for psychedelic-based drug formulations to treat Alzheimer’s, stroke, Parkinson’s and depression.
Core One Labs (CLABD) has a patent set to be filed for a biosynthetic psychedelic compound that can be produced competently and cost effectively at scale. [62]
Core One Labs (CLABD) has an existing database of over 200,000 patients.[63]
Core One Labs (CLABD) has a business model of recurring revenue through their clinic patients.
Core One Labs (CLABD) has an aggressive expansion plan to roll out clinics across Canada.
Core One Labs (CLABD) has $20 million of invested capital.[64]
Core One Labs (CLABD) is dedicated to the advancement of psychedelic treatments through research.
As you’ve seen, Core One Labs (CLABD) is a potential leader in this budding industry… even before psychedelics cross the border into the U.S. mainstream.
But savvy investors would do well to act fast.
The state of Oregon recently legalized psilocybin for therapeutic purposes.
And that’s in addition to the drug being decriminalized in four cities plus the District of Columbia.
And as we’ve recently seen with cannabis, American public opinion about the health benefits of once-controlled substances is rapidly shifting.
That’s why the bears will probably miss out on this opportunity…
While, the bulls could easily wind up cornering the market by owning a worthwhile psychedelics company like Core One Labs (CLABD).
And with the mental health fallout from COVID-19 starting to come into focus, the mental health boom could very well prove to be THE investment opportunity of the decade.
So, I urge you to discover more about psychedelics, the future of mental health, and Core One Labs (CLABD).
Check carefully because I recognize that young companies with great stories can carry a significant amount of risk… that risk ranges from being under-funded to having a small number of shares available to the public.
So, I’ll also never shy away from alerting you about the risks associated with investing in young companies, new to the stock market. That’s why I urge you always observe my three rules for accepting microcap investing risk:
Risk Reduction Rule #1: Never invest more than you can afford to lose.
Risk Reduction Rule #2: Do not chase losses. That means if the prices slide you must resist all temptation to “average down.”
Risk Reduction Rule #3: Don’t put all your dreams on one microcap. Allocate your risk capital among a handful of stocks
All that said, I think you and your financial advisor will end up in agreement, Core One Labs (CLABD) could be 2021’s top headline-making stock.
If you’re interested, talk to your broker about the insights you’ve discovered here today.* Or click here to learn more now.
Jame DiGeorgia/ InvestingTrends.com
ADVERTISEMENT DISCLAIMER
THIS PUBLICATION IS AN ISSUER-PAID ADVERTISEMENT. This paid advertisement includes a stock profile of Core One Labs. (OTCQB: CLABD). To enhance public awareness of CLABD and its securities, the issuer has provided Promethean Marketing, Inc. (“Promethean”) with a total budget of approximately 1,595,000 USD(USD) to cover the costs associated with this advertisement for a period beginning 1 April 2021 and currently set to end 22 September 2021. In connection with this effort, Promethean has paid the author of this advertisement, James DiGeorgia 23,000 USD in cash out of the total budget. The website hosting this advertisement, Investing Trends, is owned by Summit Publishing Group, Inc. (“Summit”), an affiliate of Promethean. Neither Summit nor Investing Trends have been paid to host this advertisement. As a result of this advertisement, Investing Trends may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. Promethean will retain any excess sums after all expenses are paid. James DiGeorgia is solely responsible for the contents of this advertisement. As of the date this advertisement is posted to the Investing Trends website, some or all of Promethean, Investing Trends, Summit, or James DiGeorgia, and any of their respective officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) may hold the securities of CLABD and may sell those shares during the course of this advertising campaign. This advertisement may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of CLABD, increased trading volume, and possibly an increased share price of CLABD’s securities, which may or may not be temporary and decrease once the advertising campaign has ended. To more fully understand the Investing Trends website or service, please review its full Disclaimer and Disclosure Policy located here.
* See our Important Notice and Disclaimer above for a detailed discussion on compensation, risks, atypical results, and more.
[1] https://www.wsj.com/articles/covid-19s-toll-on-u-s-business-200-000-extra-closures-in-pandemics-first-year-11618580619
[2] https://www.cnbc.com/2020/12/08/the-us-has-10-million-fewer-jobs-now-than-before-the-pandemic.html
[3] https://www.naco.org/resources/featured/american-rescue-plan-act-funding-breakdown
[4] https://everfi.com/blog/community-engagement/the-forecast-for-2021-6-key-trends-in-mental-health/
[5] https://www.sciencedirect.com/science/article/abs/pii/S0033350617302731
[6] https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a1.htm
[7] https://store.samhsa.gov/sites/default/files/d7/priv/sma14-4883.pdf
[8] https://mhanational.org/conditions/depression
[9] https://americanaddictioncenters.org/alcoholism-treatment/depression
[10] https://core1labs.com/company-news/core-one-labs-biosynthesized-psilocybin-provisional-patent-imminent
[11] https://core1labs.com/company
[12] https://core1labs.com/company
[13] https://core1labs.com/company
[14] https://core1labs.com/company
[15] https://www.globenewswire.com/news-release/2021/01/06/2154290/0/en/Behavioral-Health-Market-to-Garner-Growth-at-5-02-by-2027.html
[16] https://www.analysisgroup.com/the-growing-economic-burden-of-depression-in-the-united-states/
[17] https://core1labs.com/company
[18] https://www.globenewswire.com/news-release/2020/04/21/2019282/0/en/Global-Antidepressants-Market-2020-to-2030-COVID-19-Implications-and-Growth.html
[19] https://www.sciencedirect.com/science/article/pii/S2215036616300657
[20] https://core1labs.com/company
[21] https://www.forbes.com/sites/chrisroberts/2020/11/04/oregon-legalizes-psilocybin-mushrooms-and-decriminalizes-all-drugs/?sh=3cd706ee4b51
[22] https://www.prnewswire.com/news-releases/multi-billion-dollar-market-forecast-in-psychedelic-therapeutics-301151890.html
[23] https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows
[24] https://www.ted.com/talks/rick_doblin_the_future_of_psychedelic_assisted_psychotherapy/transcript?language=en
[25] https://www.youtube.com/watch?v=pUWaZ_wxhhg
[26] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041963/
[27] https://core1labs.com/our-focus
[28] https://core1labs.com/our-focus
[29] https://core1labs.com/our-focus
[30] https://core1labs.com/our-focus
[31] https://core1labs.com/our-focus
[32] https://core1labs.com/company
[33] https://core1labs.com/company
[34] https://core1labs.com/company
[35] https://pubmed.ncbi.nlm.nih.gov/25586396/
[36] https://core1labs.com/company
[37] https://mjbizdaily.com/what-is-next-for-federal-marijuana-reform-legalization/
[38] https://mjbizdaily.com/what-is-next-for-federal-marijuana-reform-legalization/
[39] https://mjbizdaily.com/what-is-next-for-federal-marijuana-reform-legalization/
[40] https://finance.yahoo.com/quote/ACB/history?period1=1405382400&period2=1514592000&interval=1wk&filter=history&frequency=1wk&includeAdjustedClose=true
[41] https://www.google.com/finance/quote/ACB:NASDAQ
[42] https://www.google.com/finance/quote/CGC:NASDAQ
[43] https://core1labs.com/our-focus
[44] https://core1labs.com/our-focus
[45] https://core1labs.com/company-news/core-one-labs-commences-development-on-patent-pending-psychedelic-drug-formulation-for-the-treatment-of-alzheimers-disease
[46] https://core1labs.com/our-focus
[47] https://core1labs.com/our-focus
[48] https://www.google.com/finance/quote/SBUX:NASDAQ?sa=X&ved=2ahUKEwjBv67Jg7vxAhWJg-AKHXt9D3sQ3ecFMAB6BAgWEBo
[49] https://en.wikipedia.org/wiki/Legal_status_of_psilocybin_mushrooms#_United_States
[50] https://en.wikipedia.org/wiki/Legal_status_of_psilocybin_mushrooms#_United_States
[51] https://observer.com/2020/10/why-magic-mushrooms-are-the-next-big-booming-and-legal-drug-market/
[52] https://observer.com/2020/10/why-magic-mushrooms-are-the-next-big-booming-and-legal-drug-market/
[53] https://www.pewresearch.org/fact-tank/2019/11/14/americans-support-marijuana-legalization/
[54] https://www.dailymail.co.uk/news/article-9484125/Newly-two-three-Americans-legalization-marijuana-survey-finds.html
[55] https://core1labs.com/company
[56] https://core1labs.com/company
[57] https://core1labs.com/company
[58] https://core1labs.com/company
[59] https://www.businesswire.com/news/home/20191122005452/en/FDA-grants-Breakthrough-Therapy-Designation-Usona-Institutes
[60] https://adf.org.au/insights/psilocybin-therapeutic-treatment/
[61] Call with Core One Labs Team
[62] https://core1labs.com/our-focus
[63] https://core1labs.com/our-focus
[64] https://core1labs.com/our-focus
James DiGeorgia
James DiGeorgia is the publisher, editor in chief and managing partner of WorldOpportunityInvestor.com. Among other credentials, he has 36 years of financial publishing experience.